Treatment for diabetic foot ulcers with Heberprot – P Cuban medication.

Treatment with Heberprot – P Cuban medication for diabetic foot ulcers.

Tratamiento para Pie Diabético en Cuba

The Heberprot-P, a drug that has been applied to patients with diabetic foot ulcer with a proven, to keep the limbs of patients with these ulcers.

Diabetic foot ulcer. Is an open sore or wound that generally occurs in the foot in approximately 15 percent of patients with diabetes. Six percent of diabetics have a foot ulcer should be hospitalized due to infection or other ulcer-related complication.

Therapy HEBERPROT-P fills the space of an unmet for the treatment of complex diabetic foot ulcers worldwide medical necessity

The Heberprot-P, pharmaceutical product was conceived at the Center for Genetic Engineering and Biotechnology of Cuba; the main advantages of treatment for diabetic foot ulcer Heberprot-P are:

  • UPD accelerates the healing of deep and complex.
  • Reduces the risk of amputations in patients with UPD.
  • Three weeks of treatment with this product have been sufficient to observe granulation over 80% of patients with UPD between 1 and 80 cm2.
  • Contributes significantly to improving the quality of life of patients by reducing the number and extent of surgical shunts or removal of necrotic tissue, and prevent recurrence.
  • Reduces healing time and with this, the resulting complications such as gangrene and infection or super-infection, enabling re allocate resources to patients toughest forecasts.

The results of treatment with the drug-P Heberprot observed at approximately two weeks of treatment.

Treatment with the drug Heberprot-P is indicated by a angiologist and comprises administering an intramuscular injection three times per week; offers patients improved their quality of life, resulting in a swift return to daily activities.
Trade name: Heberprot-P®
Pharmacologic Category: Agent stimulating healing and cytoprotective.
Pharmaceutical form: Injectable presented in lyophilized form in glass bulbs.
Route of administration: parenteral administration, intralesionally and perilesional.
Product Composition: Each vial contains 5 ml, depending on the dose.

Heberprot – P action is based on recombinant human growth factor (FCHrec.), By intralesional infiltration directly into the wound site.

The effect of Epidermal Growth Factor (EGF) has been extensively studied in the healing process. This is a protein, single molecule, having a molecular weight of 6045 daltons, an isoelectric point of 4.6 and consists of 53 amino acids.

Mechanism of action:
For chronic and complex wounds such as diabetic:

  • Rescue stunned cells, generally fibroblasts.
  • Induction of proliferation of fibroblasts, fibroblasts and vascular Mio- Precursors (angiogenesis NOVO).
  • Cell migration.
  • Activation of genes for extracellular matrix synthesis.
  • Acceleration of the synthesis of alpha-SMA fibroblasts mio.

The heberprot- P should be used only on prescription, along with other conventional therapies for the management of diabetic foot in patients with neuropathic and ischemic ulcers, grades 3 and 4 of the Wagner, with an area greater than 1 cm2, for stimulate the formation of useful granulation tissue that allows the closure by secondary intention or autograft skin.


  • Patients with a history of hypersensitivity to the product or any of its components.
  • Patients with a current diagnosis of oncological diseases, past or suspected existence of any type of malignancy.
  • Patients with decompensated heart disease, diabetic coma or diabetic ketoacidosis.

Adverse events:
The most common clinical adverse events reported with the use of Heberprot-P® are burning and pain at the site of application. Cases have been reported with chills and fever, in addition to local infection.
Drug Interactions:
It is not known if Heberprot-P® interacts with other topical medications is why it is recommended not to apply other topical products.

Dosage and Administration:
Heberprot-P® be administered at a rate of 75μg, diluted in 5 mL of water for injection, three times a week, via perilesional and intralesional. Administrations shall be maintained until complete granulation of the lesion, the closing of this is achieved by grafting or a maximum of 8 weeks of treatment is reached.

Treatment should be discontinued in cases where useful granulation tissue to cover the entire extension of the lesion or the area reduction is achieved to less than 1 cm2 is reached.

Infiltration should be performed after the cure of the lesions in the edges of ulcers.
If after three weeks of continuous treatment there is formation of useful granulation tissue in the ulcer bed, you should evaluate treatment and assess other factors that may hinder healing among these osteomyelitis, local infection and metabolic decontrol.






Case x 1 g .Heberprot bulb 75-P®
Case x 6 bulbs Heberprot-P® 75


Treatment with Heberprot – P Cuban medication for diabetic foot ulcers.



 Tratamiento contra la drogadicción / Vitiligo / Rehabilitación NeurológicaEscozul /  Cirugía Estética / Psoriasis / Vimang /   Alopecia / Chequeos MédicosProgramas de Ortopedia / Retinosis PigmentariaProgramas para la Tercera Edad / Programas de Oftalmología / Cirugía Máxilo Facial / Implante Dental  / Ayuda  / Información sobre Cuba / Contacto / Inicio

Una respuesta

  1. […] Fármaco cubano revoluciona tratamiento para úlcera del pie diabético. Ver en ingles […]

    Me gusta


Introduce tus datos o haz clic en un icono para iniciar sesión:

Logo de

Estás comentando usando tu cuenta de Cerrar sesión /  Cambiar )

Google+ photo

Estás comentando usando tu cuenta de Google+. Cerrar sesión /  Cambiar )

Imagen de Twitter

Estás comentando usando tu cuenta de Twitter. Cerrar sesión /  Cambiar )

Foto de Facebook

Estás comentando usando tu cuenta de Facebook. Cerrar sesión /  Cambiar )


Conectando a %s

A %d blogueros les gusta esto: